Pluripotent Stem Cell assays and pioneer predictive toxicology

Regulatory agencies meets cutting edge science to prepare the future
Leipzig – 02/28/2012

In the development of products for human use it is vital to identify compounds with toxic properties at an early stage of their development, to avoid spending time and resource on unsuitable and potentially unsafe candidate products. Human pluripotent stem cell lines offer a unique opportunity to develop a wide variety of human cell-based test systems because they may be expanded indefinitely and triggered to differentiate into any cell type. SCR&Tox aims at making use of these two attributes to provide in vitro assays for predicting toxicity of pharmaceutical compounds and cosmetic ingredients. The consortium has been designed to address all issues related with biological and technological resources to meet that goal.

SCR&Tox is intricately associated to other consortia of the “Alternative Testing” call. It has been launch in Jan 2011 to establish Proof of concept of the proposed pluripotent stem cell-based assays for toxicology. From those developments will arise a new generation of assays dedicated to predictive toxicology.

European regulatory bodies involved in the control and prospective planning of predictive toxicology testing should be specifically informed of the bases of cell-based assays that should eventually open new paradigms for this activity in the cosmetic and pharmaceutical industries worldwide.

SCR&Tox consortium is offering the possibility to discover the new possibilities its technologies are opening. A workshop is organized on the 28th February 2012 in Leipzig – Germany, open to all employees of european and national regulatory bodies (no registration fees).

The SCR&Tox workshop will also open possibilities to develop further direct interactions such as visit of SCR&Tox facilities and regular updates on technologies developments.

I wish to express on behalf of SCR&Tox, my warmest welcome

Sébastien Duprat – Director of Training

PROGRAMME 02/28/2012

08:30 – 09:00 Registration, welcome coffee

09:00 – 09:05 Welcome words
Marc Peschanski (I-Stem, France)

09:05 – 09:45 iPSC: current technologies, quality assessment and application
Simone Haupt (Life & Brain / university of Bonn, Germany)

09:45 – 10:15 Standardisation of stem cell based toxicity tests for safety assessments

Susanne Bremer-Hoffmann (JRC, Italy)

10:15 – 10:55 Industrial cell banking, tissue modelisation and assay miniaturization
Catharina Ellerström (Cellectis – Stem Cells / Cellartis SA, Sweden)

10:55 – 11:25 Regulatory considerations on the road to the clinic
Marc Peschanski (I-Stem, France)

11:25 – 12:00 Wrap up, round table discussion
Simone Haupt (University of Bonn, Germany)
Susanne Bremer-Hoffman and Francesca Pistollato (JRC, Italy)
Peter Björquist (Cellectis – Stem Cells / Cellartis SA, Sweden)
Marc Peschanski and Sébastien Duprat (I-Stem, France)

12:00 – 14:00 Lunch Break

13:00 – 14:00 Possibility to visit the SCR&Tox research facilities in Leipzig.
Andrea A. Robitzki *(Biotechnological Biomedical Center, University of Leipzig – Germany)*

	Presentations	

Pluripotent Stem Cell assays and pioneer predictive toxicology,